Goldman Sachs Reinstates Buy on 4D Molecular Therapeutics, Announces $81 Price Target
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter reinstated 4D Molecular Therapeutics (FDMT) with a Buy rating and set a price target of $81.

February 07, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs reinstated 4D Molecular Therapeutics with a Buy rating and set a price target of $81.
The reinstatement of a Buy rating by a prominent analyst at Goldman Sachs, coupled with a significant price target of $81, suggests a strong bullish outlook for FDMT. This endorsement is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100